

Caroline S Stokes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9029724/publications.pdf>

Version: 2024-02-01

51
papers

1,393
citations

411340

20
h-index

388640

36
g-index

58
all docs

58
docs citations

58
times ranked

2109
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of vitamin D metabolic markers by mass spectrometry: Recent progress regarding the “gold standard” method and integration into clinical practice. <i>Mass Spectrometry Reviews</i> , 2023, 42, 1647-1687.	2.8	19
2	Association between fat-soluble vitamins and self-reported health status: a cross-sectional analysis of the MARK-AGE cohort. <i>British Journal of Nutrition</i> , 2022, 128, 433-443.	1.2	0
3	Analytical considerations for accurately capturing the relevant species contributing to vitamin D status in liquid chromatography-tandem mass spectrometry assays. <i>Analytical Science Advances</i> , 2022, 3, 14-20.	1.2	2
4	Excess Body Weight and Gallstone Disease. <i>Visceral Medicine</i> , 2021, 37, 254-260.	0.5	10
5	Vitamin D in Preclinical Models of Fatty Liver Disease. <i>Anticancer Research</i> , 2020, 40, 527-534.	0.5	9
6	Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00131.	1.0	6
7	The Effect of the Paleolithic Diet vs. Healthy Diets on Glucose and Insulin Homeostasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 296.	1.0	15
8	Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP). <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 175-181.	0.5	43
9	L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. <i>The Cochrane Library</i> , 2019, 2019, CD012410.	1.5	59
10	Hepatic steatosis in patients with acromegaly. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00090.	1.0	10
11	Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic <i>PNPLA3</i> p.I148M Genetic Variant: An Open-Label Study. <i>Lifestyle Genomics</i> , 2019, 12, 10-17.	0.6	4
12	Medicinal Diets: From Molecules to Nutrients to Foods: Basic and Clinical Implications. <i>Current Medicinal Chemistry</i> , 2019, 26, 3372-3375.	1.2	0
13	Serum 25-hydroxyvitamin D levels and mortality risk in patients with liver cirrhosis: a protocol for a systematic review and meta-analysis of observational studies. <i>Systematic Reviews</i> , 2019, 8, 73.	2.5	1
14	Short-term Dietary Interventions for the Management of Nonalcoholic Fatty Liver. <i>Current Medicinal Chemistry</i> , 2019, 26, 3483-3496.	1.2	3
15	Effects of Gene Variants Controlling Vitamin D Metabolism and Serum Levels on Hepatic Steatosis. <i>Digestion</i> , 2018, 97, 298-308.	1.2	6
16	Rapid Quantification of 25-Hydroxyvitamin D ₃ in Human Serum by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2018, 29, 1456-1462.	1.2	17
17	Antidepressant effects of direct-acting antivirals against hepatitis C virus—Results from a pilot study. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13024.	1.7	10
18	Analytical Methods for Quantification of Vitamin D and Implications for Research and Clinical Practice. <i>Anticancer Research</i> , 2018, 38, 1137-1144.	0.5	21

#	ARTICLE	IF	CITATIONS
19	L-Ornithine L-Aspartate for Hepatic Encephalopathy: A Systematic Review with Meta-Analyses of Randomised Controlled Trials. <i>Journal of Clinical and Experimental Hepatology</i> , 2017, 7, S65-S66.	0.4	2
20	Quantification of the 3 ¹ ± and 3 ¹ ² epimers of 25-hydroxyvitamin D3 in dried blood spots by LC-MS/MS using artificial whole blood calibration and chemical derivatization. <i>Talanta</i> , 2017, 165, 398-404.	2.9	20
21	Design and validation of a German version of the GSRS-IBS - an analysis of its psychometric quality and factorial structure. <i>BMC Gastroenterology</i> , 2017, 17, 139.	0.8	7
22	Vitamin D supplementation: less controversy, more guidance needed. <i>F1000Research</i> , 2016, 5, 2017.	0.8	23
23	Short-Term Hypocaloric High-Fiber and High-Protein Diet Improves Hepatic Steatosis Assessed by Controlled Attenuation Parameter. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e176.	1.3	29
24	Triple Quadrupole Versus High Resolution Quadrupole-Time-of-Flight Mass Spectrometry for Quantitative LC-MS/MS Analysis of 25-Hydroxyvitamin D in Human Serum. <i>Journal of the American Society for Mass Spectrometry</i> , 2016, 27, 1404-1410.	1.2	29
25	How to prepare a manuscript fit for purpose for submission and avoid getting a "desk reject". <i>Rapid Communications in Mass Spectrometry</i> , 2016, 30, 2573-2576.	0.7	6
26	Assessment of 3-epi-25-hydroxyvitamin D levels during cholecalciferol supplementation in adults with chronic liver diseases. <i>Applied Physiology, Nutrition and Metabolism</i> , 2016, 41, 1311-1317.	0.9	9
27	Chemotyping the distribution of vitamin D metabolites in human serum. <i>Scientific Reports</i> , 2016, 6, 21080.	1.6	27
28	The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP). <i>Liver International</i> , 2016, 36, 418-426.	1.9	24
29	Vitamin D supplementation reduces depressive symptoms in patients with chronic liver disease. <i>Clinical Nutrition</i> , 2016, 35, 950-957.	2.3	37
30	Analysis of Vitamin D Metabolites by Mass Spectrometry. , 2016, , 1-20.		2
31	A genetic variant in the promoter of phosphate-activated glutaminase is associated with hepatic encephalopathy. <i>Journal of Internal Medicine</i> , 2015, 278, 313-322.	2.7	6
32	A simple micro-extraction plate assay for automated LC-MS/MS analysis of human serum 25-hydroxyvitamin D levels. <i>Journal of Mass Spectrometry</i> , 2015, 50, 275-279.	0.7	24
33	HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. <i>Journal of Hepatology</i> , 2015, 62, 980-981.	1.8	42
34	Analysis of vitamin D metabolic markers by mass spectrometry: Current techniques, limitations of the "gold standard" method, and anticipated future directions. <i>Mass Spectrometry Reviews</i> , 2015, 34, 2-23.	2.8	115
35	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 614.	2.4	2
36	Associations of circulating natriuretic peptides with haemodynamics in precapillary pulmonary hypertension. <i>Respiratory Medicine</i> , 2015, 109, 1213-1223.	1.3	7

#	ARTICLE	IF	CITATIONS
37	Vitamin D deficiency is associated with mortality in patients with advanced liver cirrhosis. <i>European Journal of Clinical Investigation</i> , 2014, 44, 176-183.	1.7	58
38	Vitamin D modulates biliary fibrosis in ABCB4-deficient mice. <i>Hepatology International</i> , 2014, 8, 443-452.	1.9	32
39	Ursodeoxycholic Acid and Diets Higher in Fat Prevent Gallbladder Stones During Weight Loss: A Meta-analysis of Randomized Controlled Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1090-1100.e2.	2.4	73
40	Pharmacological interventions for the primary prevention of gallbladder stones in adults. <i>The Cochrane Library</i> , 2014, , .	1.5	0
41	Genetics of biliary lithiasis from an ethnic perspective. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 119-125.	0.7	21
42	Genetics and treatment of bile duct stones. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 329-335.	1.0	8
43	Vitamin D in chronic liver disease. <i>Liver International</i> , 2013, 33, 338-352.	1.9	138
44	Transporters in cholelithiasis. <i>Biological Chemistry</i> , 2012, 393, 3-10.	1.2	8
45	Gallstones: Environment, Lifestyle and Genes. <i>Digestive Diseases</i> , 2011, 29, 191-201.	0.8	78
46	Omega-3 Fatty Acids in the Treatment of Psychiatric Disorders. <i>Drugs</i> , 2005, 65, 1051-1059.	4.9	196
47	Short Communication. <i>Nutritional Neuroscience</i> , 2004, 7, 247-249.	1.5	39
48	Diets for primary prevention of gallbladder stones in adults. <i>The Cochrane Library</i> , 0, , .	1.5	2
49	Bile acid derivatives for people with primary biliary cholangitis. <i>The Cochrane Library</i> , 0, , .	1.5	0
50	L-ornithine L-aspartate for people with cirrhosis and hepatic encephalopathy. <i>The Cochrane Library</i> , 0, , .	1.5	2
51	Bile acid derivatives for people with primary sclerosing cholangitis. <i>The Cochrane Library</i> , 0, , .	1.5	0